Where can I buy shares of Zyne?
Shares of ZYNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
What is the upside for zynerba pharmaceuticals (Zyn) stock?
Their forecasts range from $7.25 to $18.00. On average, they anticipate Zynerba Pharmaceuticals' share price to reach $10.56 in the next twelve months. This suggests a possible upside of 229.0% from the stock's current price. View analysts' price targets for Zynerba Pharmaceuticals or view top-rated stocks among Wall Street analysts.
How much is a share of zynerba worth?
One share of ZYNE stock can currently be purchased for approximately $3.21. How much money does Zynerba Pharmaceuticals make? Zynerba Pharmaceuticals has a market capitalization of $132.31 million and generates $90 thousand in revenue each year.
What are analysts'target prices for zynerba Pharmaceuticals'stock?
7 brokers have issued 1-year target prices for Zynerba Pharmaceuticals' stock. Their predictions range from $11.00 to $36.00. On average, they anticipate Zynerba Pharmaceuticals' share price to reach $22.00 in the next year.
ZineOne Comparisons
ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore e
ZineOne Signals
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
What is ZineOne?
Predictive engagement platform that helps businesses target users, identify visitor's intent and more.
ZineOne Alternatives
Best For: JMP users make amazing discoveries saving endangered species, creating life-saving drugs and designing energy-efficient products. See more at jmp.com/applications.
What is the Zynerba symbol?
Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE ."
What is Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on research and development of rare and near-rare neuropsychiatric conditions. The firm offers Zygel product, which formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.
Does Zynerba pay dividends?
Zynerba Pharmaceuticals does not currently pay a dividend.
